Overview

Paradromics is pursuing the highest-channel-count BCI system with the Connexus platform, designed to capture unprecedented neural signal resolution for complex motor and communication tasks. Founded in 2015 and headquartered in Austin, the company combines venture funding of $105 million with $18 million in NIH and DARPA grants, reflecting strong government validation.

Technical Specifications

The Connexus system features 1,600 recording channels, roughly 1.5x more than competing penetrating electrode approaches. This high channel density is engineered to capture distributed neural populations across motor and language areas simultaneously, enabling decoding of complex speech intentions from neural signals.

Clinical Milestones

Paradromics achieved first-in-human recording in June 2025 during an epilepsy surgery, demonstrating safety of the high-channel implant in a human patient. The company subsequently received FDA approval for its Connect-One clinical study in November 2025, establishing a pathway to recruit paralyzed patients with speech impairment.

Market Positioning

By focusing on speech restoration rather than gross motor control, Paradromics targets a distinct patient population and addresses a high-value unmet need. Speech BCIs represent a larger addressable population than mobility restoration alone.